Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the submission of a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) by Janssen Pharmaceutical K.K. (Janssen) seeking approval of a new subcutaneous (SC) formulation of daratumumab, an intravenous (IV) treatment approved for patients with multiple myeloma.

Halozyme (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Halozyme (HALO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Halozyme Therapeutics, Inc. (NASDAQ: HALO), will participate in the Bank of America Securities 2020 Healthcare Conference. This conference is being hosted virtually. Dr. Helen Torley, president and chief executive officer, will provide an overview of the company on Thursday, May 14 at 5:00 p.m. ET / 2:00 p.m. PT.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen-Cilag International NV (Janssen) received a Committee for Medicinal Products for Human Use (CHMP) Positive Opinion from the European Medicines Agency (EMA) recommending approval of a DARZALEX® (daratumumab) subcutaneous (SC) formulation for the treatment of adult patients with multiple myeloma in frontline and relapsed/refractory settings. The CHMP's Positive Opinion for daratumumab SC formulation applies to all current daratumumab indications including newly diagnosed and transplant-ineligible patients, as well as relapsed or refractory patients.

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2020 on Monday, May 11 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the first quarter ended March 31, 2020 following the close of trading.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the company will receive a $15 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered under the Collaboration and License Agreement between the two companies. The milestone payment is associated with the first commercial sale in the United States of Janssen's DARZALEX FASPROTM (daratumumab and hyaluronidase - fihj) utilizing ENHANZE®, which was recently approved by the U.S. Food and Drug Administration.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that due to the emerging public health impact of the coronavirus outbreak (COVID-19), to support the health and well-being of our employees and stockholders, and to comply with the State of California's stay at home order, its Board of Directors has approved a change in the location of its 2020 Annual Meeting of Stockholders to a virtual-only shareholder meeting instead of an in-person meeting. As previously announced, the Annual Meeting will be held on Thursday, April 30, 2020 at 8:00 a.m. local time. Stockholders will not be able to attend the Annual Meeting physically in person.

Anyone researching Halozyme Therapeutics, Inc. (NASDAQ:HALO) might want to consider the historical volatility of the...

Artisan Mid Cap Fund recently released its Q1 2020 Investor Letter, a copy of which you can download below. The fund posted a return of -11.55% for the quarter (investor class), outperforming their benchmark, the Russell Midcap Index which returned -27.07% in the same quarter. You should check out Artisan Mid Cap Fund’s top 5 […]

Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business and Elaine Sun, our Chief Financial Officer who will review our financial results for the first quarter 2020. Thank you, Al. And it's really a delight to welcome Elaine to her first call as our Chief Financial Officer at Halozyme.

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, 2020 and provided an update on its recent corporate activities and outlook.

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -300.00% and -35.57%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

As of late, it has definitely been a great time to be an investor Halozyme Therapeutics

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its collaborator Janssen Biotech, Inc. (Janssen) has received approval from the U.S. Food and Drug Administration (FDA) for DARZALEX FASPRO™ (daratumumab hyaluronidase human- fihj). DARZALEX FASPRO™ is approved in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients.

Halozyme (HALO) reports wider-than-expected Q1 loss. Shares down.

Top Ranked Momentum Stocks to Buy for May 15th

Barclays (LON:BARC) analyst Gena Wang maintained a Hold rating on Halozyme (NASDAQ:HALO) Therapeutics on Tuesday, setting a price target of $21, which is approximately 15.39% below the present share price of $24.82.